Stock Option And Stock Award Plans (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary Of Stock Options Outstanding

summary of stock options outstanding at December 31, 2020, 2019 and 2018, and changes during those years, is presented below:

		Option Exercise Price/Share
	Number of Options	Range					Weighted Average
Outstanding at December 31, 2017	608,520	$	15.65	to	$	24.84	$	19.75
Granted	451,083	19.35		to	19.35		19.35
Forfeited and expired	(96,089)	15.65		to	24.84		19.58
Exercised	(73,398)	15.65		to	22.49		18.15
Outstanding at December 31, 2018	890,116	15.65		to	24.84		19.69
Granted	758,287	18.48		to	18.48		18.48
Forfeited and expired	(10,000)	19.40		to	19.40		19.40
Exercised	(9,500)	19.40		to	19.40		19.40
Outstanding at December 31, 2019	1,628,903	15.65		to	24.84		19.13
Granted1	638,074	10.75		to	14.62		11.90
Modification for special cash dividend1	701,535	10.75		to	14.62		11.90
Forfeited and expired1	(141,074)	10.75		to	24.84		11.87
Exercised	—	—		to	—		—
Outstanding at December 31, 20201	2,827,438	$	10.75	to	$	22.49	$	13.55
1.The option exercise price per share reflects the reduction to the exercise prices of outstanding stock options impacted by the modification due to the anti-dilution provisions in the stock-based compensation plan.

Summary Of Additional Information On Stock Options Outstanding And Exercisable

The following table summarizes additional information about stock options outstanding and exercisable at December 31, 2020:

					Options Outstanding at December 31, 2020						Options Exercisable at December 31, 2020
						Weighted Average			Aggregate Intrinsic Value					Aggregate Intrinsic Value
Range of Exercise Prices					Shares	Remaining Contractual Life	Exercise Price				Shares	Weighted Average Exercise Price
$	—	to	$	13.99	1,598,700	5.4 years	$	12.11	$	7,338,799	425,219	$	12.50	$	1,785,553
13.99		to	18.65		1,059,138	4.4 years	14.64		2,209,408		692,973	14.66		1,447,785
18.65		to	23.32		169,600	2.1 years	20.27		—		169,600	20.27		—
Total					2,827,438	4.9 years	$	13.55	$	9,548,207	1,287,792	$	14.68	$	3,233,338

Summary Of Additional Information On Non-Vested Restricted Stock Outstanding

The following table summarizes additional information about unvested restricted stock outstanding at December 31, 2020, 2019 and 2018:

	Unvested Restricted Stock					Maximum Unvested Restricted Stock Units Issuable Upon Satisfaction of Certain Performance Criteria
	Number of Shares	Weighted Avg. Grant Date Fair Value/Share		Grant Date Fair Value (In thousands)		Number of Shares	Weighted Avg. Grant Date Fair Value/Share		Grant Date Fair Value (In thousands)
Outstanding at January 1, 2018	206,676	$	16.15	$	3,337	172,133	$	15.78	$	2,716
Granted	119,915	17.39		2,085		61,227	17.35		1,062
Vested	(64,702)	18.31		(1,185)		—	—		—
Forfeited	(17,153)	15.84		(272)		(48,651)	13.23		(644)
Outstanding at December 31, 2018	244,736	16.20		3,965		184,709	16.97		3,134
Granted	185,422	18.46		3,423		57,442	18.34		1,053
Vested	(117,834)	14.76		(1,739)		(69,926)	10.96		(766)
Forfeited	(26,389)	16.11		(425)		(24,562)	11.51		(283)
Outstanding at December 31, 2019	285,935	18.27		5,224		147,663	21.25		3,138
Granted	155,138	14.55		2,257		34,275	15.25		523
Vested	(148,709)	17.39		(2,586)		(37,370)	17.38		(649)
Forfeited	(57,385)	17.00		(976)		(32,066)	17.36		(557)
Outstanding at December 31, 2020	234,979	$	16.68	$	3,919	112,502	$	21.82	$	2,455

Share-based Payment Arrangement, Stock Appreciation Right, Activity

The following table summarizes SARs activity in 2020 as no SARs were granted prior to January 1, 2020 since 1992:

		Exercise Price/Share
	Number of SARs	Range					Weighted Average
Outstanding at January 1, 2020	—	$	—	to	$	—	$	—
Granted1	387,252	10.75		to	19.64		11.60
Modification for special cash dividend	71,402	10.75		to	19.64		11.60
Forfeited and expired	(82,214)	10.75		to	19.64		11.39
Exercised	—	—		to	—		—
Outstanding at December 31, 2020	376,440	$	10.75	to	$	19.64	$	11.64
1.The SARs exercise price per share reflects the reduction to the exercise prices of outstanding SARs as a results of the modification to the awards pursuant to the nondiscretionary anti-dilution provisions in the related SARs grant agreements.